Jguirim-Souissi Imen, Jelassi Awatef, Addad Faouzi, Hassine Majed, Najah Mohamed, Ben Hamda Khaldoun, Maatouk Faouzi, Ben Farhat Mohamed, Bouslema Ali, Rouis Mustapha, Slimane Mohamed Naceur
Unit of Research, Genetic and Biologic Factors of Atherosclerosis, Faculty of Medicine, CHU Fattouma, Bourguiba, Monastir, Tunisia.
Am J Cardiol. 2007 Jul 1;100(1):23-7. doi: 10.1016/j.amjcard.2007.01.069. Epub 2007 May 7.
Several matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) have been implicated in the development and outcome of coronary artery disease (CAD). We investigated whether MMP-12 and TIMP-1 levels were associated with risk, severity, and outcome of CAD. Plasma MMP-12 and TIMP-1 levels are measured in 50 and 44 patients with CAD, respectively, by enzyme-linked immunosorbent assay. Of all patients, 16 were taking statins. Patients who were not on statins were classified into 3 groups according to number of >50% stenotic vessels. Compared with 29 volunteers without CAD, patients without statins (n = 34) had higher MMP-12 concentrations (1.71 vs 1.08 ng/ml, p = 0.021). MMP-12 levels were significantly lower in patients with than in those without statin treatment (0.99 vs 1.71 ng/ml, p = 0.008). There was no association between MMP-12 levels and number of >50% stenotic vessels. MMP-12 concentrations were not associated with outcome of CAD. However, plasma TIMP-1 levels were associated with restenosis independently of number of stenotic vessels and age (p = 0.035) but not with risk or severity of CAD. In conclusion, plasma MMP-12 concentration was associated with the presence of CAD. Statin therapy decreases plasma MMP-12 levels in patients with CAD. Increased TIMP-1 levels may prevent restenosis after angioplasty.
几种基质金属蛋白酶（MMPs）和金属蛋白酶组织抑制剂（TIMPs）与冠状动脉疾病（CAD）的发生发展及预后有关。我们研究了MMP - 12和TIMP - 1水平是否与CAD的风险、严重程度及预后相关。通过酶联免疫吸附测定法分别检测了50例CAD患者和44例CAD患者的血浆MMP - 12和TIMP - 1水平。所有患者中，16例正在服用他汀类药物。未服用他汀类药物的患者根据狭窄血管>50%的数量分为3组。与29名无CAD的志愿者相比，未服用他汀类药物的患者（n = 34）MMP - 12浓度更高（1.71对1.08 ng/ml，p = 0.021）。服用他汀类药物的患者MMP - 12水平显著低于未服用者（0.99对1.71 ng/ml，p = 0.008）。MMP - 12水平与狭窄血管>50%的数量无关。MMP - 12浓度与CAD的预后无关。然而，血浆TIMP - 1水平与再狭窄相关，独立于狭窄血管数量和年龄（p = 0.035），但与CAD的风险或严重程度无关。总之，血浆MMP - 12浓度与CAD的存在相关。他汀类药物治疗可降低CAD患者的血浆MMP - 12水平。TIMP - 1水平升高可能预防血管成形术后的再狭窄。
